Miscellaneous bone disorders

Endocrine Development

Volumn 16, Issue , 2009, Pages 191-217

  Mughal, Zulf ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBISPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; INDOMETACIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; PAMIDRONIC ACID; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ALBRIGHT SYNDROME; AUTOSOMAL RECESSIVE DISORDER; BONE DISEASE; BONE FRAGILITY; BONE MALFORMATION; BONE MARROW TRANSPLANTATION; BONE MASS; BONE RADIOGRAPHY; BRAIN CALCIFICATION; CAFFEY DISEASE; CAMURATI ENGELMANN DISEASE; CHILDHOOD DISEASE; CHONDRODYSPLASIA; CLEIDOCRANIAL DYSPLASIA; DRUG MEGADOSE; DYSPLASIA; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FIBROUS DYSPLASIA; FRAGILITY FRACTURE; GENE ACTIVATION; GENE MUTATION; GENERALISED ARTERIAL CALCIFICATION OF INFANCY; GERODERMA OSTEODYSPLASTICUM; HUMAN; HYPOPHOSPHATASIA; IATROGENIC DISEASE; JANSEN METAPHYSEAL CHONDRODYSPLASIA; JUVENILE OSTEOPOROSIS; KIDNEY TUBULE ACIDOSIS; LIMB DEFORMITY; NORRIE DISEASE; OSSIFYING MYOSITIS; OSTEOCLAST; OSTEOCLAST POOR AUTOSOMAL RECESSIVE INFANTILE OSTEOPETROSIS; OSTEOCLAST RICH AUTOSOMAL RECESSIVE INFANTILE OSTEOPETROSIS; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; OSTEOPOROSIS PSEUDOGLIOMA SYNDROME; PAGET BONE DISEASE; PRIORITY JOURNAL; PROGRESSIVE OSSEOUS HETEROPLASIA; PYKNODYSOSTOSIS; RARE DISEASE; REVIEW; RICKETS; SCLEROSTOSIS; VAN BUCHEM DISEASE;

BONE AND BONES; BONE DENSITY; BONE DISEASES; BONE DISEASES, DEVELOPMENTAL; CHILD; HUMANS; OSTEOPETROSIS; OSTEOPOROSIS;

EID: 68149144075     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000223696     Document Type: Review

References (43)

1. Frattini A, Orchard PJ, Sobacchi C, et al: Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000;25:343-346.
2. Frattini A, Pangrazio A, Susani L, et al: Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res 2003;18:1740-1747.
3. Pangrazio A, Poliani PL, Megarbane A, et al: Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res 2006;21:1098-1105.
4. Wilson CJ, Vellodi A: Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch Dis Child 2000;83:449-452.
5. Kasper D, Planells-Cases R, Fuhrmann JC, et al: Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 2005;24:1079-1091.
6. Sobacchi C, Frattini A, Guerrini MM, et al: Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007; 39:960-962.
7. Guerrini MM, Sobacchi C, Cassani B, et al: Human osteoclast-poor osteopetrosis with hypogamma-globulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008;83:64-76.
8. Dini G, Floris R, Garaventa A, et al: Long-term follow-up of two children with a variant of mild autosomal recessive osteopetrosis undergoing bone marrow transplantation. Bone Marrow Transplant 2000;26:219-224.
9. Van Wesenbeeck L, Odgren PR, Coxon F P, et al: Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest 2007;117:919-930.
10. Waguespack SG, Hui SL, Dimeglio LA, Econs MJ: Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J Clin Endocrinol Metab 2007;92:771-778.
11. Sly WS, Hewett-Emmett D, Whyte M P, Yu YS, Tashian RE: Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 1983;80:2752-2756.
12. Whyte M P, Wenkert D, Clements KL, McAlister WH, Mumm S: Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-463.
13. Gelb BD, Shi G P, Chapman HA, Desnick RJ: Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236- 1238.
14. Brunkow ME, Gardner JC, Van Ness J, et al: Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577-589.
15. Balemans W, Patel N, Ebeling M, et al: Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002;39:91-97.
16. Boyden LM, Mao J, Belsky J, et al: High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-1521.
17. Kinoshita A, Saito T, Tomita H, et al: Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 2000;26:19-20.
18. Castro GR, Appenzeller S, Marques-Neto JF, Bertolo MB, Samara AM, Coimbra I: Camurati-Engelmann disease: failure of response to bisphosphonates: report of two cases. Clin Rheumatol 2005;24:398- 401.
19. Shore EM, Xu M, Feldman GJ, et al: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006;38:525-527.
20. Kaplan F, International Clinical Consortium on Fibrodysplasia Ossificans Progressiva: The medical management of fibrodysplasia ossificans progressiva: current treatment considerations.3:182 http:/www.ifopa.org/pdf/ FOPRXGuidelinesFinal-8-27- 08.pdf
21. Adegbite NS, Xu M, Kaplan FS, Shore EM, Pignolo RJ: Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am J Med Genet [A] 2008;146A:1788-1796.
22. Ai M, Heeger S, Bartels CF, Schelling DK: Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet 2005;77:741- 753.
23. Rauch F, Travers R, Norman ME, Taylor A, Parfitt AM, Glorieux FH: Deficient bone formation in idiopathic juvenile osteoporosis: a histomorphometric study of cancellous iliac bone. J Bone Miner Res 2000;15:957-963.
24. Hartikka H, Makitie O, Mannikko M, et al: Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 2005;20: 783-789.
25. Cundy T, Hegde M, Naot D, et al: A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002;11:2119-2127.
26. Cundy T, Wheadon L, King A: Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 2004;19: 703-711.
27. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM: Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005;353:918- 923.
28. Hunter AG, Martsolf JT, Baker CG, Reed MH: Geroderma osteodysplastica: a report of two affected families. Hum Genet 1978;40:311-324.
29. Newman WG, Clayton-Smith J, Metcalfe K, et al: Geroderma osteodysplastica maps to a 4 Mb locus on chromosome 1q24. Am J Med Genet [A] 2008; 146A:3034-3037.
30. Hennies HC, Kornak U, Zhang H, et al: Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin. Nat Genet 2008;40:1410- 1412.
31. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH: Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003;88:4569-4575.
32. Mornet E: Hypophosphatasia. Best Pract Res Clin Rheumatol 2008;22:113-127.
33. Whyte MP: Enzyme Defects and the Skeleton; in Rosen CJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 7. Washington, American Society for Bone and Mineral Research, 2008, pp 454-458.
34. Whyte M P, Kurtzberg J, McAlister WH, et al: Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res 2003;18:624-636.
35. Cahill RA, Wenkert D, Perlman SA, et al: Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts. J Clin Endocrinol Metab 2007;92:2923-2930.
36. Millan JL, Narisawa S, Lemire I, et al: Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res 2008;23:777-787.
37. Whyte M P, Mumm S, Deal C: Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 2007;92:1203-1208.
38. Rutsch F, Ruf N, Vaingankar S, et al: Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003;34:379-381.
39. Rutsch F, Böyer P, Nitschke Y, et al: Hypophosphatemia, hyperphosphaturia and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy (GACI). Circulation Cardiovasc Genet 2008;1:133-140.
40. Schipani E, Langman CB, Parfitt AM, et al: Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N Engl J Med 1996;335:708-714.
41. Caffey J, Silverman W: Infantile cortical hyperostosis, preliminary report on new syndrome. Am J Roentg 1945;54:1-16.
42. Gensure RC, Makitie O, Barclay C, et al: A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J Clin Invest 2005;115:1250- 1257.
43. Otto F, Kanegane H, Mundlos S: Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 2002;19:209-216.